Clinical effect of recombinant human growth hormone for interventing central precocious puberty in children

Abstract

Objective To investigate clinical effect of recombinant human growth hormone (rhGH) for interventing central precocious puberty in children, to provide reference for clinical treatment. Methods 80 patients with growth deceleration slows CCP were selected, when height growth rate below 4cm/year, 40 patients on the basis of joint GnRHa used rhGH treatment were selected as the observation group, and the remaining 40 patients refused to use rhGH, continued to use of GnRHa treatment were selected as the control group.After treatment predicted height, height, bone age, growth rate and other indicators were compared. Results In observation group, the actual height Ht, predicted height PAH, the growth rate Gv, serum insulin-like growth factor-1 (IGF-1) after treatment were (144.48±6.59)cm, (154.94±4.52)cm, (4.43±0.64)cm/6months, (132.25±8.84)ng/mL, compared to before treatment, the differences were statistically significant (t=6.548, P<0.01; t=5.734, P<0.01; t=28.869, P<0.01; t=20.65, P<0.01), compared with the control group, the differences were significant (t=3.943, P<0.01; t=4.759, P<0.01; t=28.247, P<0.01; t=20.882, P<0.01), there were no differences in other indices; hormones FSH, LH and other indicators of the two groups before and after treatment, and blood sugar, thyroid indicators showed no abnormality. Conclusion Recombinant human growth hormone in the treatment of central precocious puberty deceleration in children does not increase bone age, which will help improve the growth rate and predicted height, which worthy of clinical application. Key words: Human growth hormone; Gonadotropin-releasing hormone; Child development; Sex characteristics